Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers
van Keimpema L, de Man RA, Drenth JP. Somatostatin analogues reduce liver volume in
polycystic liver disease. Gut 2008 September;57(9):1338-9.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Liver volume reduction
24 weeks
No
Joost PH Drenth, PhD
Principal Investigator
Radboud University Nijmegen Medical Center
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
NL16194.091.07
NCT00771888
April 2008
August 2009
Name | Location |
---|